Deal Snapshot: A lot of the French drug maker’s interest has focused on biologics, but the Skyhawk deal shows it has maintained a keen interest in innovative small molecules as well.
Who: Sanofi and Skyhawk Therapeutics, Inc.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.
Adstiladrin sales hit €70m in first full year on the market
Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.
